Since AMD3100 inhibits SDF1-mediated non-malignant CD34+ cell migration we also expect ibrutinib to do the same, however, as we have observed previously we expect ibrutinib to inhibit pro-survival signals including SCF mediated and to a lesser extent IL-3 and GM-CSF in AML [19]. The gene discussed is IL3; the disease is acute myeloid leukemia.